Nebenwirkungen · Gazyvaro
Gazyvaro 1 000 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 22
HOS-129931 · Präparat HOS-096817
The incidence of IRRs was higher in the Gazyvaro plus chlorambucil arm compared to the rituximab plus chlorambucil arm. The incidence of IRRs was 66% with the infusion of the first 1 000 mg of Gazyvaro (20% of patients experiencing a Grade 3-4 IRR). Overall, 7% of patients experienced an IRR leading to discontinuation of Gazyvaro. The incidence of IRRs with subsequent infusions was 3% with the second 1 000 mg dose and 1% thereafter. No Grade 3-5 IRRs were reported beyond the first 1 000 mg infusions of Cycle 1.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-17T10:49:00Z · SHA-256 18e252f824981860d284b6a8d0590c4e67726398fe4cfebbac1cb10441aeb96a · Passage 0301b2fba61d70dcfc4c4b23387253bc004e88dab957ef1ce86a70359c0bdb07 · Zeichen 11245–11761 im Abschnitt